search
Back to results

Observational Study of Survival Outcomes of Stage IV Cancer Patients

Primary Purpose

Stage IV Cancer (Solid Tumors Only), Survival

Status
Unknown status
Phase
Locations
China
Study Type
Observational
Intervention
Sponsored by
Cure Cancer Worldwide Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an observational trial for Stage IV Cancer (Solid Tumors Only) focused on measuring Stage IV cancer, Survival

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presenting with Stage IV cancer (solid tumors only)

Exclusion Criteria:

  • Patient declines inclusion

Sites / Locations

  • Yang Ling Demonstration Zone Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Arm Label

1. Eligible RCT/Elect RCT

2. Eligible RCT/Elect LDC

3. Eligible RCT/Elect PCO

4. Ineligible RCT/Elect LDC

5. Ineligible RCT/Elect PCO

Arm Description

Eligible for regular chemotherapy, elects and receives regular chemotherapy

Eligible for regular chemotherapy, elects and receives low-dose chemotherapy

Eligible for regular chemotherapy, elects and receives palliative care only

Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy

Ineligible for regular chemotherapy, elects and receives palliative care only

Outcomes

Primary Outcome Measures

survival

Secondary Outcome Measures

Full Information

First Posted
April 27, 2013
Last Updated
April 27, 2013
Sponsor
Cure Cancer Worldwide Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT01843985
Brief Title
Observational Study of Survival Outcomes of Stage IV Cancer Patients
Official Title
Observational Study of Survival Times of Stage IV Cancer Patients
Study Type
Observational

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Unknown status
Study Start Date
June 2013 (undefined)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cure Cancer Worldwide Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy. If eligible, patients are offered traditional chemotherapy, low-dose chemotherapy, or palliative care. If ineligible, patients are offered low-dose chemotherapy or palliative care. Patients will be monitored for 5 years and survival data recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stage IV Cancer (Solid Tumors Only), Survival
Keywords
Stage IV cancer, Survival

7. Study Design

Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1. Eligible RCT/Elect RCT
Arm Description
Eligible for regular chemotherapy, elects and receives regular chemotherapy
Arm Title
2. Eligible RCT/Elect LDC
Arm Description
Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
Arm Title
3. Eligible RCT/Elect PCO
Arm Description
Eligible for regular chemotherapy, elects and receives palliative care only
Arm Title
4. Ineligible RCT/Elect LDC
Arm Description
Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
Arm Title
5. Ineligible RCT/Elect PCO
Arm Description
Ineligible for regular chemotherapy, elects and receives palliative care only
Primary Outcome Measure Information:
Title
survival
Time Frame
months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presenting with Stage IV cancer (solid tumors only) Exclusion Criteria: Patient declines inclusion
Study Population Description
primary care clinic
Sampling Method
Non-Probability Sample
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
gary smith
Phone
5207492035
Email
garylsmith2@msn.com
Facility Information:
Facility Name
Yang Ling Demonstration Zone Hospital
City
Yang Ling
State/Province
Shaanxi
Country
China

12. IPD Sharing Statement

Learn more about this trial

Observational Study of Survival Outcomes of Stage IV Cancer Patients

We'll reach out to this number within 24 hrs